2024-518088-37-01CompletedPhase 1
A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Dec 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- First submitted
- 20 Nov 2024
- Start date
- 4 Dec 2024
- Lead sponsor
- TILT Biotherapeutics Oy
- Diseases
- Melanoma
- EU CT number
- 2024-518088-37-01
- EudraCT number
- 2021-005127-20
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 9
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Docrates Oy | Helsinki | Finland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.